UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~February 926, ~~2020~~2021

OWC Pharmaceutical Research Corp.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in its ~~Charter~~charter)

Commission File No.: 0-54856

Delaware	0-54856	98-0573566
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

Delaware		98-0573566
(State of Incorporation)		(I.R.S. Employer Identification No.)

2 Ben Gurion Street, Ramat Gan, Israel 4514760

2 Ben Gurion Street, Ramat Gan, Israel		4514760
(Address of Principal Executive Offices)		(Zip Code)

(Address of Principal Executive Offices) (Zip Code)

~~Registrant’s Telephone Number, including area code: 972 (0) 3-758-2657~~N/A

~~Not~~(Former ~~Applicable~~name or former address, if changed since last report)

~~(Former~~Check ~~name~~the orappropriate ~~former~~box ~~address,~~below if ~~changed~~the ~~since~~Form ~~last~~8-K ~~report.)~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~Check the~~[ ~~appropriate~~] ~~box~~Written ~~below~~communications ifpursuant ~~the Form 8-K filing is intended~~ to ~~simultaneously~~Rule ~~satisfy~~425 ~~the filing obligation of the registrant~~ under ~~any of~~ the ~~following~~Securities ~~provisions~~Act (~~see~~17 ~~General~~CFR ~~Instruction A~~230.~~2. below~~425):

[ ] ~~Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ]~~ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Securities registered~~[ ] Pre-commencement communications pursuant to ~~Section~~Rule 1214d-2(b) ofunder the Exchange Act: (17 CFR 240.14d-2(b))

~~Title~~[ of] ~~each~~Pre-commencement ~~class~~communications ~~Trading~~pursuant ~~Symbol~~to ~~Name~~Rule of13e-4(c) ~~each~~under ~~exchange~~the onExchange ~~which~~Act ~~registered~~(17 ~~Common~~CFR ~~Stock OWCP OTCPQB~~240.13e-4(c))

~~Indicate by~~Item ~~check~~5.01 ~~mark~~Changes ~~whether the registrant is an emerging growth company as defined~~ in ~~Rule~~Control ~~405~~ of ~~the Securities Act of 1933 (§230~~Registrant.~~405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).~~

~~Emerging~~On ~~growth~~December ~~company~~13, ~~[ ]~~2020, Pursuant to Section 5(g) of the Certificate of Designations, Preferences and Rights of the Series A Convertible Preferred Stock, Discover Growth Fund, LLC waived the 4.99% limitation on beneficial ownership provided for therein. The notice was effective on February 16, 2021, sixty-one calendar days after the date of such notice.

IfOn anFebruary ~~emerging~~26, ~~growth company~~2021, ~~indicate~~the bySeries ~~check~~A ~~mark~~Preferred ifstockholder ~~the~~executed ~~registrant~~a ~~has~~majority ~~elected~~written ~~not~~consent toof ~~use~~stockholder ~~the~~to ~~extended~~remove ~~transition~~Ziv ~~period for~~Turner ~~complying~~as ~~with~~the ~~any~~sole ~~new~~director orof ~~revised~~the ~~financial~~Company, ~~accounting~~and ~~standards~~to ~~provided~~appoint ~~pursuant~~David toKugelman ~~Section~~as ~~13(a)~~the sole director of the ~~Exchange Act~~Company. ~~[ ]~~

Item 8 5.0102 ~~Other~~Departure ~~Events.~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~December~~February 1026, ~~2020~~2021, ~~One~~Ziv ~~World~~Turner ~~Cannabis~~was ~~Ltd.~~removed ~~(“OWC-Israel”),~~as anthe ~~Israeli~~sole ~~subsidiary~~director of ~~OWC Pharmaceutical Research Corp., filed a petition under~~ the ~~Insolvency and Rehabilitation Law~~Company, ~~2018 in the Israeli Haifa District Court. As stated in the petition, OWC-Israel is insolvent at the present time~~ and ~~met~~David ~~the~~Kugelman ~~conditions~~was ~~required~~appointed ~~under~~as ~~Israeli law for submitting a petition to~~ the ~~court.~~ ~~OWC-Israel~~sole ~~stated that it believes that there were no alternatives to filing the petition and having the court find a suitable~~director ~~solution~~of ~~for~~ the ~~benefit of its creditors~~Company.

On March 2, 2021, Zvi Ritterband was removed as the sole director of the Company’s wholly-owned Israeli subsidiary, One World Cannabis Ltd., and David Kugelman was appointed as the sole director of the subsidiary.

Mr. Kugelman, age 56, is the President of Atlanta Capital Partners, LLC, a private equity and investor relations consulting firm, and the Publisher of the small-cap stock newsletter, OTC Stock Review. Mr. Kugelman has been in the Investment industry since 1986 and has held the National Association of Securities Dealers Series 7, 24, 63, and 66 licenses, as well as the Certified Financial Manager designation. In the past, he has worked for Thomson McKinnon, Bear Stearns, and Merrill Lynch, as well as two regional Investment Banking Firms. In addition to managing investments for both individuals and corporate clients, Mr. Kugelman structured transactions servicing middle market institutional funds by providing corporate clients access to public financial markets including external funding, strategic alliances, restructurings, acquisitions, and business strategy formation.

At Merrill Lynch, Mr. Kugelman was a Financial Advisor and Investment Advisor Representative working mainly with middle market institutional funds, corporations, family offices and Defined Benefit plans. Acting in a financial advisory role, he specialized in retirement and estate planning, tax and asset strategies, philanthropic vehicles, and banking and lending services. A fondness for the pursuit of growth-stocks prompted Mr. Kugelman to leave Merrill Lynch in February, 2003 and formed Atlanta Capital Partners, LLC.

As President of Atlanta Capital Partners, LLC, Mr. Kugelman has provided strategic business planning and public relations services to a diverse number of small and large public and privately held companies. Atlanta Capital Partners, LLC takes a unique approach to investor relations by becoming an investor in a company. Drawing on over 30 years of contacts in the investment industry, Mr. Kugelman has carefully built relationships worldwide with Retail Brokerage Firms, Investment Bankers, Analysts, Fund Managers, and Independent Investors by introducing them to undiscovered opportunities.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

OWC ~~PHARMACEUTICAL~~Pharmaceutical ~~RESEARCH~~Research ~~CORP~~Corp. By: /s/ ~~Ziv~~David ~~Turner~~Kugelman Name: ~~Ziv~~David ~~Turner~~Kugelman Title: ~~Chief~~Chairman ~~Executive~~of ~~Officer~~the Board of Directors

~~Dated~~Date: ~~December~~March 145, ~~2020~~2021

Filing Compare · OWC Pharmaceutical Research Corp.